Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain

European Journal of Public Health

Volumn 18, Issue 6, 2008, Pages 674-680

  Gauthier, Aline ^a,e   Martín Escudero, Victoria ^b   Moore, Lee ^a   Ferko, Nicole ^c   De Sanjosé, Silvia ^d   Pérez Escolano, Isabel ^b   Catalá López, Ferrán ^b   Ferrer, Elena ^d   Bosch, F Xavier ^d  

^a i3 Innovus   (United Kingdom)

^b GLAXOSMITHKLINE   (Spain)

^c i3 Global   (Canada)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e NONE   (United Kingdom)

Author keywords

Mass screening; Papillomavirus vaccines; Spain; Uterine cervical neoplasms

Indexed keywords

ADJUVANT; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL PROTOCOL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PRECANCER; PREVALENCE; PRIORITY JOURNAL; SPAIN; STATISTICAL MODEL; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SENSITIVITY AND SPECIFICITY; SPAIN; UTERINE CERVICAL NEOPLASMS;

EID: 56749092154     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckn064     Document Type: Article

References (53)

1. Bosch FX, Qiao YL, Castellsagué X. The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynaecol Obstet 2006;94(Suppl 1):S8-S21.
2. de Sanjosé S, Almirall R, Lloveras B, et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93.
3. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504-10.
4. Font R. Estimation of the human papillomavirus risks and regressionprogression times [in Spanish]. XXII Annual Meeting of the Spanish Society of Epidemiology, Cáceres, Spain: 27-29 October 2004.
5. Gonzalez C, Ortiz M, Canals J, et al. Higher prevalence of human papillomavirus infection in migrant women from Latin America in Spain. Sex Transm Infect 2006;82:260-2.
6. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
7. Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Available from: http://www-dep.iarc.fr (date last accessed 20 February 2006).
8. de Sanjosé S, García AM. Secondary prevention: The current state of cervical cancer screening in Spain [in Spanish]. 4th Monography of the Spanish Society of Epidemiology, 2006,131-8.
9. de Sanjosé S, Cortés X, Méndez C, et al. Age at sexual initiation and number of sexual partners in the female Spanish population. Results from the AFRODITA survey. Eur J Obstet Gynecol Reprod Biol 2008 May 20. [Epub ahead of print].
10. Munoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med 2003;348:518-27.
11. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
12. Gall SA, Teixeira J, Wheeler WM. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/ 18 VLP AS04 candidate vaccine (14 April 2007). Los Angeles, CA: American Association for Cancer Research (AACR).
13. Paavonen J, Jenkins D, Bosch F, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
14. Harper DM, Gall S, Naud P, et al. Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow up through 6.4 years in women vaccinated with Cervarix (GSKs HPV 16/18 AS04 candidate vaccine). Miami, Florida, USA: Society of Gynecologic Oncologists (SGO) Conference (9 March 2008).
15. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and costeffectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
16. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 2005;115:268-75.
17. Berkhof J, de Bruijne MC, Zielinski GD, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006;118:1759-68.
18. Castellsagué X. Coverage and factors associated with cervical cancer screening results from the AFRODITA study, a population-based survey in Spain. 23rd International Papillomavirus Conference: Prague, Czech Republic, 1-7 September 2006.
19. Hopman EH, Kenemans P, Helmerhorst TJ. Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature. Obstet Gynecol Surv 1998;53:97-106.
20. Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Cytology (SEC), Spanish Association of Colposcopy and Cervical Pathology (AEPCC). Human papillomavirus infection [in Spanish]. Consensus document, 2002.
21. Puig-Tintoré LM, Castellsagué X, Torne A, et al. Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis 2008;12:82-9.
22. Rash RM, Torné A, Castro M, et al. Evaluating the costs of follow-up and treatment of women with abnormal cervical cytology in Spain. 244. 2007. Barcelona, Spain, Book of Abstracts, IV Annual Meeting Health Technology Assessment International (HTAi) (17 June 2007).
23. Rash B, Van Kriekinge G, Standaert B. Comparing management patterns and associated costs for women with abnormal cervical cytology in 5 different countries. Copenhagen, DK: ISPOR 9th Annual European Congress (28 October 2006).
24. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
25. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
26. Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
27. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8.
28. Data collected at the Hospital Creu Roja of L'Hospitalet, Barcelona (Spain). 1999.
29. Vilaplana E, Puig-Tintoré LM, Cortés J. Abnormal cytology results, Spanish survey [in Spanish]. AEPCC Newsletter 2006;20:10.
30. Globocan 2002 Database. Available at: http://www-dep.iarc.fr (Accessed 20 February 2006).
31. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents, IARC Vol. VII. Lyon: IARC Scientific publications No 143, 1997.
32. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents, Vol. VIII. Lyon: IARC Scientific publications No 155, IARC, 2002.
33. Spanish National Statistics Institute (INE) 2004. Deaths according to causes by age group and sex in 2003. Available at: http://www.ine.es/inebase/ index.html.
34. Kohli M, Ferko N, Martin A, et al. Estimating the long-term impact of the prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007;96:143-50.
35. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
36. Spanish Ministry of Health & Consumer Affairs 2007. National Health System Interterritorial Council unanimously approved the inclusion of the human papillomavirus vaccine in the National Health System vaccination calendar [in Spanish]. Available at: http://www.msc.es/gabinetePrensa/notaPrensa/ desarrolloNotaPrensa.jsp?id=992 (Accessed 23 November 2007). (Press Release, 10 October 2007).
37. INE. Encuesta de Salud y Hábitos Sexuales 2003. Available from: http://www.ine.es/prodyser/pubweb/saludyhs03/saludyhs03.htm (Accessed 9 November 2007).
38. Spanish National Statistics Institute (INE) 2004. Population data by age group and sex in 2003. Available at: http://www.ine.es/inebase/index.html. (Accessed 7 February 2007).
39. Gall SA, Teixeira J, Wheeler WM, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 VLP AS04 candidate vaccine. Presented at the 2007 meeting of the American Association for Cancer Research (AACR), Los Angeles, CA, 14-18 April 2007. Abstract 4900.
40. Hepatitis B vaccination coverage in adolescents, school year 2004. Autonomous regions of Spain. Available at: http://www.vacunasaep.org/ profesionales/coberturas.htm (Accessed 7 February 2007).
41. Ferko N, Debicki D, Bamfi F, et al. Estimating the long-term health and economic impact of a prophylactic human papillomavirus (HPV) 16/18 vaccine with cross-protection on the burden of cervical disease in Italy. ISPOR 10th Annual European Congress, Dublin, Ireland: 22 October 2007.
42. Siebert U, Schwarz TF, Schneider A, et al. A cost-effective analysis of a human papillomavirus (HPV) 16/18 vaccine with cross-protection benefit in Germany. ISPOR 10th Annual European Congress, Dublin, Ireland: 22 October 2007.
43. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
44. Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus - a health technology assessment. Health Technol Assess 2007;9:79-96.
45. La Torre G. Health Technology Assessment Della Vaccinazione Anti-HPV. Italian J Public Health 2007;4:55-81.
46. Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer 2004;91:84-91.
47. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
48. Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25.
49. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18:3263-82.
50. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677-86.
51. Fernandez Calvo MT, Hernandez Rubio A, Rosell Aguilar I. Cervical cancer screening in Spain. Eur J Cancer 2000;36:2250-4.
52. Bell S, Porter M, Kitchener H, et al. Psychological response to cervical screening. Prev Med 1999;24:610-6.
53. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24(Suppl 3):S171-7.